García-Jiménez C, Tovilla-Canales JL, Jiménez-Martínez MC

Language: Spanish
References: 16
Page: 209-213
PDF size: 95.70 Kb.

ABSTRACT

Purpose: To determine CD57+T cells and CD4+CD25+FOXP3T cells in patients with different clinical-stages of ocular Graves’ disease.
Methods: Patients (n=15) were divided into 3 groups: Group A with diagnosis of inactive Graves disease (I), Group B with active Graves disease without treatment (AST), Group C with active Graves disease with treatment (ACT). Peripheral blood mononuclear cells were obtained and were labeled with fluorescent antibodies against CD4, CD8, CD25, CD57, and FOXP3. Results were analyzed by flow-cytometry and T test used for statistical analysis.
Results: In ACT patients the percentage of CD4+T cells was similar to I patients and was diminished 1.1 times in contrast to AST patients. We observed 1.9 times more percentage of CD4+CD25+ Tcells in AST patients than in I patients. Both subsets of CD57+ Tcells, CD4+ and CD8+T cells were significantly increased in ACT patients than in AST patients. CD4+CD25+T cells were increased 3.4 times more in ACT patients than in AST patients. FOXP3 expression on CD4+CD25+T cells was similar in all groups.
Conclusions: It is possible that the regulation of Graves’ hyperthyroidism depends on more than one regulatory T cell subset. Functional studies are needed to know the real function of these T cells in Graves’ disease.

REFERENCES

1. Garrity J A, Van R S. Pathogenesis of Graves Ophthalmopathy: Implications for Prediction, Prevention, and Treatment. Am J Ophthalmol 2006; 142:147-153.

2. Pérez Moreiras JV, Coloma Bockos JE, Sánchez P. Orbitopatía Tiroidea (Fisiopatología, Diagnóstico y Tratamiento). Arch Soc Esp Oftalmol 2003; 78:407-432.

3. Cockram CS. Mixing modalities: exploring the options for Graves Ophthalmopathy. Hong Kong Med J 2005; 11(5).

4. Dolman P, Rootman J. VISA Classification for Graves Orbitopathy. Opthal Plast Reconstr Surg 2006; 22(5):319-324.

5. Prabhakar B, Bahn R, Smith T. Current Perspective on the Pathogenesis of Graves´ Disease and Ophthalmopathy. Endocrine Rev 2003; 24:802-835.

6. Wiersinga & Prummel. Patogenesis in Grave’s Ophthalmopathy-Current Understanding. J Clin Endocrinol Metab 2006; 86(2):501-503.

7. Volper R. The Pathogenesis in Grave’s Disease. Endocr Pract 1995; 1(2):103-115.

8. Karagiannidis CH, Akdis M, Holopainen P, Woolley N, Hense G y cols. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004; 114:1425-1433.

9. Barrat F, Cua D, Boonstra A, Richards D, Crain Ch y cols. In Vitro Generation of Interleukin 10-producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper type 1 (Th1)-and Th2-inducing Cytokines. J Exp Med 2002; 195(5) 603-616.

10. Bartanela L, Pinchera A, Marcocci C. Management of Graves ´ Ophthalmopathy: Reality and Perspectives. EndocrRev 2000; 21:168-199.

11. Stephens LA, Mottet C, Mason D, Powrie F. Human CD4(+)cd25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 2001; 31:1247-1254.

12. Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M. A peripheral circulating compartment of natural naïve CD4 T regs. J Clin Invest 2005; 115: 1953-1962.

13. Hueman MT, Stojadinovic A, Storrer CE y cols. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and CM-CSF vaccine. Breast Cancer Res Treat 2006; 98:17-29.

14. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Ann Rev Immunol 2004; 22: 531-562.

15. Saitoh O, Nagayama Y. Regulation of Graves´ Hyperthyroidism with Naturally Ocurring CD4+CD25+ Regulatory T Cells in a Mouse Model. Endocrinology 2006; 147:2417-2422.

16. Chen X, Murakami T, Oppenheim J, Howard OM. Differential response of murine CD4+ CD25+ and CD4+CD25+ cells to dexamethasone-induced cell death. Eur J Immunol 2004; 34:859-869.